Tsayawa magani zai iya haifar da sake dawowa MS a wasu
Tysabri (natalizumab) wani magani ne na gyaran cututtukan da ake amfani da shi wajen magance sake dawowa a cikin mutane tare da ƙwayar sclerosis (MS) . Yana hana ƙwayar rigakafin sel don ƙetare shinge na kwakwalwa na jini wanda ya raba kwakwalwa da kashin baya daga sauran jiki. Wadannan kwayoyin halitta ne zasu iya haifar da lalacewar jijiyoyi kamar yadda suke ba da gangan su shafe su daga abin da suke karewa (wanda aka sani da ƙuƙwalwar ƙwayar myelin ).
Cibiyar Abincin da Drug ta Amurka (FDA) ta amince da Tysabri don amfani a cikin MS na kwayoyin halitta (ba za a hade shi da sauran hanyoyin kwantar da hankali) kuma an gudanar da shi a cikin kowane kwana 28.
Risks Associated Tare da Tysabri Amfani
Duk da yake an nuna Tysabri don rage komawa cikin mutane tare da MS ta hanyar kashi 68 cikin dari, ba tare da damuwa ba. A shekara ta 2005, FDA ta ba da sanarwar fata ta gargaɗin marasa lafiya da likitoci cewa Tysabri yana kusa da mutum biyu daga kowane kamfani 1,000 da suka kamu da kwakwalwar kwakwalwa wanda aka sani da ci gaba mai mahimmanci .
Wani damuwar da aka fi sani da shi shine abin da aka sani da sake komawa inda gurguzu ko katsewa daga miyagun ƙwayoyi ya haifar da sake dawowa da bayyanar MS ta hanyar dawowa , a wasu lokuta mafi muni fiye da lokacin da aka fara maganin.
Fahimtar Ƙaunin Yanayin
An fara gano tasirin Tysabri a 2007 lokacin da masu bincike na Dutch suka binciki MRI da suka yi la'akari da mutanen da suke shan Tysabri amma ya tsaya a lokacin da aka kwantar da miyagun ƙwayoyi daga kasuwa saboda damuwa da PML.
A cikin wannan watanni 15 na rashin lafiya, masu binciken kimiyya sun gano cewa yawancin raunuka a cikin tsarin da ke tsakiya sun karu daga kimanin 3.43 a farkon magani zuwa 10.32 bayan an dakatar da magani.
Ba abin mamaki ba ne, ba a ganin wannan tasirin ya ci gaba da tsanantawa a cikin mutanen da suka yi magani fiye da lokaci.
A hakikanin gaskiya, ba kawai ba ne. Bisa ga binciken, wadanda suka kamu da maganin Tysabri na da sau biyar fiye da wadanda suka kasance a kan maganin duk lokacin nazarin (kimanin 36 infusions).
Irin wannan binciken da aka yi a shekarar 2014 ya goyi bayan wannan ikirarin kuma ya tabbatar da cewa an raguwa da farfadowa da alaka da kusan sau biyu a cikin hadari na sake dawowa. Ƙarin game da duk da haka shi ne gaskiyar cewa kashi ɗaya cikin huɗu na waɗannan mutane sun sake komawa bayan da aka dakatar da Tysabri fiye da kafin farawa.
Abin da Wannan ke faɗa mana
Masana kimiyya ba su san dalilin da ya sa hakan ya faru ba. Haka kuma an lura da wasu kwayoyi MS, ciki har da Gilenya (fingolimod) , kuma babu sauran fahimta game da abin da za a iya yi don hana shi.
Abin da muka sani shi ne: mutanen da suka fi girma haɗari su ne waɗanda suka ɗauki watanni kawai na Tysabri sannan su dakatar. Idan magani tare da Tysabri an bada shawarar, kai ne mai yin haƙuri ya buƙaci yi wa jiyya ka kuma tsaya tare da shi. Ba za ku iya ɗaukar ranaku na ƙwayoyi masu tsattsauran ra'ayi ba ko yanke shawarar dakatar da idan kuma lokacin da kuka ji daɗi.
Dole ne magani ya kamata a umurce shi da wani kwararren likita wanda zai iya ƙayyade idan kuma lokacin da ba a bukatar Tysabri.
> Sources:
> Fox, R .; Cri, et al. "Ciwon rashin lafiya na MS a RESTORE: wani zaman lafiya na 24-hutu na natalizumab nazarin maganin katsewa." Nazarin Halitta 2014; 82 (17): 1491-8.
> Sorensen, P .; Koch-Henrikson, H .; Petersen, T. et al. "Komawa ko sake dawowa daga sake dawowa daga asibiti bayan da aka dakatar da lafiyar natalizumab a cikin marasa lafiya MS." J Neurol . 2014; 261 (6): 1170-7.
> Vellinga, M .; Castelijns, J .; Barkhof, F. et al. "Sanya dakatar da karuwa a cikin ayyukan T2 a cikin likitoci marasa lafiya na Natalizumab." Ma'anar ilimin halitta. 2008; 70 (13): 1150-1.